[{"id":"475a7d05-25ee-4633-ae5e-c6600c4536e9","acronym":"","url":"https://clinicaltrials.gov/study/NCT06408194","created_at":"2024-05-11T04:17:51.062Z","updated_at":"2024-07-02T16:35:01.945Z","phase":"Phase 1","brief_title":"Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies","source_id_and_acronym":"NCT06408194","lead_sponsor":"Stanford University","biomarkers":" CD22","pipe":"","alterations":" ","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kymriah (tisagenlecleucel-T) • firicabtagene autoleucel (CRG-022)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 05/13/2024","start_date":" 05/13/2024","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-05-22"},{"id":"d0063cdd-ab4b-4009-8105-73c4b7241cf5","acronym":"IRB-50836","url":"https://clinicaltrials.gov/study/NCT04088890","created_at":"2021-01-18T20:00:46.615Z","updated_at":"2024-07-02T16:35:15.877Z","phase":"Phase 1","brief_title":"Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies","source_id_and_acronym":"NCT04088890 - IRB-50836","lead_sponsor":"Stanford University","biomarkers":" CD22","pipe":" | ","alterations":" CD22 positive • CD22 expression • CD20 negative","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive • CD22 expression • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous • firicabtagene autoleucel (CRG-022)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 09/12/2019","start_date":" 09/12/2019","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2037","study_completion_date":" 12/30/2037","last_update_posted":"2024-03-07"},{"id":"a371a01d-3ae1-4151-8cf6-c3f5a72a47d9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05507827","created_at":"2022-08-19T17:10:05.391Z","updated_at":"2024-07-02T16:35:18.561Z","phase":"Phase 1","brief_title":"Safety of Myeloablative Conditioning, Orca-T, and Allogeneic, Donor-Derived CD19/CD22-CAR (Chimeric Antigen Receptor) T Cells in Adults With B-cell Acute Lymphoblastic Leukemia (ALL)","source_id_and_acronym":"NCT05507827","lead_sponsor":"Dr. Melody Smith, MD, MS","biomarkers":" CD19 • KMT2A • CRLF2 • CD22 • HLA-DRB1 • HLA-B • HLA-C","pipe":" | ","alterations":" KMT2A rearrangement • MLL rearrangement • CD19 expression • CRLF2 rearrangement","tags":["CD19 • KMT2A • CRLF2 • CD22 • HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2A rearrangement • MLL rearrangement • CD19 expression • CRLF2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Orca-T • firicabtagene autoleucel (CRG-022)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 08/18/2022","start_date":" 08/18/2022","primary_txt":" Primary completion: 01/01/2037","primary_completion_date":" 01/01/2037","study_txt":" Completion: 01/01/2037","study_completion_date":" 01/01/2037","last_update_posted":"2024-02-20"},{"id":"b2fd0720-c684-4f4d-8475-75c34a4514c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04088864","created_at":"2021-01-18T20:00:46.042Z","updated_at":"2024-07-02T16:35:19.768Z","phase":"Phase 1","brief_title":"CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies","source_id_and_acronym":"NCT04088864","lead_sponsor":"Stanford University","biomarkers":" CD22","pipe":" | ","alterations":" CD22 positive • CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive • CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous • firicabtagene autoleucel (CRG-022)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 01/10/2020","start_date":" 01/10/2020","primary_txt":" Primary completion: 10/31/2023","primary_completion_date":" 10/31/2023","study_txt":" Completion: 09/10/2036","study_completion_date":" 09/10/2036","last_update_posted":"2024-02-12"}]